Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 13, 2008. The report details a specific corporate action regarding the repurchase and cancellation of the company's own ordinary shares, executed under authority granted by shareholders at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on share capital movements.
- Shares Repurchased: 2,170,000 Ordinary shares of 25 pence each.
- Repurchase Date: May 13, 2008.
- Price per Share: 1,125.60 pence.
- Treasury Shares Held: 484,194,158 shares (representing 9.02% of total voting rights).
- Shares in Issue: 5,365,701,012 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of the company's share capital through the cancellation of 2,170,000 repurchased shares. Consequently, the number of shares in issue decreased, while the proportion of Treasury shares held by the company now represents 9.02% of total voting rights.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer or solicitation to purchase securities.
Key Facts for Investor Verification
- Verify the total cost of the share buyback (2,170,000 shares at 1,125.60 pence each).
- Confirm the updated total voting rights denominator (5,365,701,012 shares) for disclosure threshold calculations.
- Note that the repurchased shares were cancelled rather than held indefinitely in treasury, though the company retains a significant treasury holding from prior periods.